Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Clene ( (CLNN) ) is now available.
On May 11, 2026, Clene Inc. amended its December 2024 senior secured convertible promissory notes with Kensington Clene 2024, 4Life Research and La Scala Investments, extending the maturity to the earlier of August 13, 2027 or a change in control and deferring planned $1 million monthly principal and interest payments until maturity. The move, involving noteholders with close commercial and governance ties to Clene, effectively pushes all principal and accrued interest to the new maturity date, easing near-term cash outflows and complementing its broader financing activities.
In its first-quarter 2026 update released on May 14, the company reported a successful FDA Type C meeting in early 2026, with regulators indicating that CNM-Au8 data may support a New Drug Application for ALS under the accelerated approval pathway. Clene detailed plans to file the NDA in the third quarter of 2026, start the RESTORE-ALS Phase 3 trial in early 2027, and highlighted January and May equity financings plus the debt amendment as extending its cash runway into late 2026 and potentially into 2027, despite an $8.1 million quarterly net loss and higher financing-related expenses.
Clene ended March 31, 2026 with $5.9 million in cash and cash equivalents, up modestly from year-end 2025 but set to be bolstered by a $7 million May 2026 offering and possible future warrant exercises tied to NDA acceptance. The company sharply reduced research and development as well as general and administrative expenses year over year, largely through lower ALS program and personnel costs, while other expense swung to a $6 million net charge due mainly to warrant-related accounting and higher interest on a larger debt load.
The most recent analyst rating on (CLNN) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
The score is held back primarily by very weak financial performance (large ongoing losses, cash burn, and negative equity). Offsetting this, technicals show strong upward price momentum, and corporate updates are positive with potential regulatory progress for CNM-Au8 and fresh financing to support near-term development milestones. Valuation provides limited support due to losses and no dividend yield data.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Clene Inc., based in Salt Lake City with R&D and manufacturing operations in Maryland, is a late clinical-stage biopharmaceutical company developing therapies that improve mitochondrial health and protect neuronal function in neurodegenerative diseases, including ALS, Parkinson’s disease and multiple sclerosis. Its lead candidate, CNM-Au8, is an oral suspension of gold nanocrystals designed to enhance cellular energy production, drive neuroprotection and remyelination, and reduce oxidative stress in central nervous system cells.
The company works through its subsidiary Clene Nanomedicine, Inc. and focuses on late-stage development of CNM-Au8 for ALS and MS, supported by expanded access programs and NIH-sponsored studies. Clene also maintains license and supply relationships for non-pharmaceutical products with partners such as 4Life Research, integrating commercial collaborations alongside its clinical pipeline.
Average Trading Volume: 490,620
Technical Sentiment Signal: Buy
Current Market Cap: $76.56M
See more data about CLNN stock on TipRanks’ Stock Analysis page.